Immutep’s Lead Most cancers Drug Exhibits Promising 2-12 months Survival Information In Lung Most cancers Trial – Immutep (NASDAQ:IMMP)

On Thursday, Immutep Restricted IMMP launched information from the INSIGHT-003 Section 1 trial of eftilagimod alpha (efti) together with Merck & Co Inc’s MRK Keytruda (pembrolizumab) and chemotherapy for first-line therapy of metastatic non-squamous non-small cell lung most cancers (1L NSCLC) sufferers.

The survival information as of knowledge cutoff of Oct. 15 from the triple mixture remedy in sufferers no matter PD-L1 expression with a minimal followup of twenty-two months (N=21) reveals:

• Median General Survival (OS) of 32.9 months.
• Median Development-Free Survival (PFS) of 12.7 months.
• 24-month General Survival (OS) of 81.0%.

Additionally Learn: Australia Primarily based Most cancers Centered Immutep’s Lead Most cancers Drug Exhibits ‘Significant Response’ In Untreated Head & Neck Most cancers, Inventory Soars

The corporate compares the info with the 22.0-month median OS, 9.0-month median PFS, and 24-month OS fee of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC no matter PD-L1 expression.

Marc Voigt, CEO of Immutep, stated, “The general survival and progression-free survival information from this mature cohort of sufferers in INSIGHT-003 with almost a 2-year minimal followup exceeds our expectations.”

Information from all evaluable sufferers to this point (N=40) demonstrates vital enchancment in General Response Charge (ORR) throughout all ranges of PD-L1 expression in comparison with historic management:

• 75.0% ORR versus 62.1% ORR in sufferers with excessive PD-L1 expression.
• 58.8% ORR versus 49.2% ORR in sufferers with low PD-L1 expression.
• 47.4% ORR versus 32.3% ORR in sufferers with damaging PD-L1.
• On this all-comer PD-L1 trial, the 55.0% ORR and 87.5% Illness Management Charge (DCR) are from the next breakdown of sufferers by PD-L1 expression: excessive PD-L1 expression (N=4), low PD-L1 expression (N=17), and damaging PD-L1 (N=19).
• In comparison with the final 1L NSCLC affected person inhabitants, every of those PD-L1 ranges represents roughly one-third, INSIGHT-003 is biased in the direction of low and damaging PD-L1 sufferers who’re sometimes much less attentive to anti-PD-1 remedy.
• In these sufferers with low and damaging PD-L1 expression (36 of 40 sufferers), the triple mixture achieved a 52.8% ORR and 86.1% DCR.

INSIGHT-003, a multi-centre examine led by the Frankfurt Institute of Medical Most cancers Analysis IKF, is nearing completion of affected person enrolment.

Further information updates from this trial are anticipated in 2025 and past.

Value Motion: IMMP inventory is up 9.6% at $2.05 ultimately verify Thursday.

Learn Subsequent:

Photograph: Shutterstock